Lateral Flow Assays Market: Growth, Size, Share, and Trends

Report Code MD 4158
Published in Jul, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Lateral Flow Assays Market by Product (Kits, Readers), Application (STI, HEP, TB, Cardiac Marker, Pregnancy, Drug Abuse, Food Safety), Sample (Blood, Urine, Saliva), Technique (Sandwich, Competitive), End User (Hospitals), and Region - Global Forecast to 2030

Overview

The global lateral flow assays market, valued at US$7.93 billion in 2024, stood at US$8.51 billion in 2025 and is projected to advance at a resilient CAGR of 8.0% from 2025 to 2030, culminating in a forecasted valuation of US$12.52 billion by the end of the period. The persistent rise in infectious diseases worldwide demands fast, accessible diagnostics, boosting the adoption of LFAs in diverse environments from hospitals and clinics to homes and remote clinics. Moreover, an aging global demographic is increasing the need for routine monitoring of chronic and cardiac conditions, encouraging broader use of home-based and point-of-care LFA solutions. Innovations such as smartphone-compatible readers, AI-powered analysis, and multiplex-capable assays further support this shift, improving usability, connectivity, and diagnostic precision. At the same time, extensive deployment of home testing kits, including pregnancy, fertility, and infectious markers self-tests, has boosted consumer acceptance and comfort with LFA devices, while regulatory approvals for POC and home-based LFAs reinforce market expansion.

Adoption is tempered by notable constraints. LFAs often exhibit lower sensitivity and specificity than molecular or lab-based tests, leading to false-positive or false-negative outcomes and hindering widespread clinical acceptance.

Lateral Flow Assays Market

Attractive Opportunities in the Lateral Flow Assays Market

Asia Pacific

The growth of the lateral flow assays market in Asia Pacific is strongly supported by the increasing infectious disease burden, rising awareness around early diagnostics, and expanding access to decentralized healthcare.

Rising awareness of quality healthcare and the growing need for technologically integrated devices in clinical settings are contributing to the increased demand for efficient lateral flow assays in the region.

The region’s large and aging population, coupled with a rising middle-class population, along with improving healthcare infrastructure and increasing healthcare expenditure in emerging economies, further supports market expansion.

The Asia Pacific is projected to be the fastest-growing region due to its rising geriatric population.

Government initiatives aimed at healthcare modernization, coupled with growing investments in digital health, are further enhancing the market potential for medical connectors in Asia Pacific.

Global Lateral Flow Assays Market Dynamics

DRIVER: High prevalence of infectious diseases

Despite notable advancements in sanitation and medical care, the global burden of infectious diseases remains substantial. While non-communicable diseases continue to be the leading causes of illness and death, infectious diseases still pose a serious public health challenge worldwide. According to the World Health Organization’s Global Tuberculosis Report 2024, tuberculosis (TB) emerged as the top infectious disease killer in 2023, overtaking COVID-19. That year, approximately 8.2 million people were newly diagnosed with TB. As of April 2024, the WHO reported over 7.6 million dengue cases globally, including 3.4 million confirmed infections, more than 16,000 classified as severe, and upwards of 3,000 related deaths. Dengue has seen a sharp rise globally in the past five years, with the Americas experiencing the most dramatic increase. By the end of April 2024, reported cases in the Americas alone had exceeded 7 million—surpassing the previous annual record of 4.6 million cases in 2023. This figure is nearly three times higher than what was reported during the same period in 2023, underscoring the accelerating severity of the outbreak. This high prevalence of infectious diseases creates significant demand for advanced assays, which include lateral flow assays.

RESTRAINT: Inconsistent results of lateral flow assay tests

While lateral flow assay (LFA) tests provide advantages such as rapid turnaround time, user-friendliness, and affordability, a major drawback lies in their variable accuracy and reliability, especially when compared to more established laboratory techniques like ELISA or PCR.

LFAs often face challenges related to sensitivity and specificity, especially in situations where the concentrations of analytes are close to the assay’s detection limit. This can occur when the levels of the substances being tested are very low, making it difficult for the assay to accurately identify them. Additionally, variations in sample handling procedures can further compromise the accuracy of the results. These challenges may lead to false negatives, where an analyte is not detected when it is actually present, or false positives, where the assay incorrectly identifies the presence of an analyte. Such inaccuracies in test results can significantly impact clinical decision-making, potentially resulting in inadequate patient care and suboptimal health outcomes.

For example, in tuberculosis screening, some antigen-based LFA tests have exhibited reduced sensitivity in HIV-positive patients, likely due to lower bacterial loads, contributing to missed diagnoses. Likewise, in malaria diagnostics, certain LFA tools have shown diminished ability to detect low-parasite-density cases, which is especially problematic in low-transmission regions or during elimination efforts.

 

OPPORTUNITY: Evolving applications of lateral flow assays

Over the past two decades, lateral flow assays (LFAs) have undergone significant advancements, transitioning from traditional applications in infectious disease detection to a wide range of uses in point-of-care (POC) and diagnostic settings. These innovative assays are now instrumental in non-invasive saliva-based diagnostics and behavioral health screenings, providing swift evaluations of both physical and mental health. In agriculture, LFAs are utilized to detect genetically modified organisms and assess crop quality, promoting food safety. They also play a critical role in biowarfare agent detection, such as anthrax, enhancing security measures against biological threats. Additionally, LFAs are employed in environmental monitoring to identify contaminating enzymes in manufacturing facilities, ensuring product safety, while in food microbiology, they are essential for detecting harmful pathogens like E. coli, Salmonella, and Listeria, thereby protecting public health and preventing foodborne illnesses.

OraSure Technologies (US) is a prominent player in the field of salivary lateral flow assay (LFA) testing. Saliva-based LFAs have become increasingly popular, particularly for drug abuse detection, and several of these systems have received FDA clearance for marketing. However, it's important to note that these tests are primarily qualitative in nature.

CHALLENGES: Limited reimbursements for lateral flow assay products

Reimbursement challenges have significantly hindered the widespread adoption of lateral flow assay (LFA)-based diagnostic tests in various countries, particularly as healthcare expenditures rise due to factors like an aging population and the increasing prevalence of chronic diseases. Insurance providers are increasingly scrutinizing the necessity and value of new diagnostic tools, especially in light of the shift from traditional fee-for-service models to value-based reimbursement systems that prioritize patient outcomes over the quantity of services provided. Consequently, diagnostic tests that primarily support clinical decision-making without directly influencing treatment pathways often struggle to obtain adequate reimbursement, resulting in reduced utilization and underfunding. This cycle not only limits the practical application of LFA-based tests but also diminishes their visibility and perceived value in improving healthcare outcomes.

These reimbursement limitations are significantly affecting the growth of the LFA diagnostics market in several regions. For example, in the UK, the National Health Service (NHS) is responsible for approximately 75% of healthcare reimbursements. In NHS primary care, coverage is limited to prescribed lateral flow devices, such as cryptococcal antigen (CrAg) tests used to detect cryptococcosis. However, there is no dedicated reimbursement policy for non-prescribed LFA kits, including those for cardiac markers or pregnancy testing.

Global Lateral Flow Assays Market Ecosystem Analysis

The ecosystem market map of the lateral flow assays market comprises the elements present in this market and defines these elements with a demonstration of the bodies involved. It includes products along with the distribution channels and end users. The product category includes products by type, such as kits & reagents and readers. Manufacturers of various lateral flow assays include organizations involved in research, product development, optimization, and launch. Distributors include third parties and e-commerce sites linked with the organization for the marketing of lateral flow assay products. Research and product development include in-house research facilities, contract research organizations, and contract development and manufacturing organizations that play a key role in outsourcing services for product development to manufacturers. The end customers are the key stakeholders in the supply chain of the lateral flow assays market. On the other hand, investors/funders and health regulatory bodies are the major influencers in this market.

Lateral Flow Assays Market
 

By product, the kits & reagents segment is projected to be for the largest segment through 2030.

Based on product, the lateral flow assays market is segmented into lateral flow readers and kits & reagents. The kits and reagents segment emerged as the predominant force within the lateral flow assays market. This significant market share is largely driven by an increasing demand for rapid diagnostic solutions that are convenient and accessible for both healthcare providers and consumers. Specifically, there is a notable rise in the popularity of point-of-care and at-home testing options for various applications, including the detection of infectious diseases, pregnancy testing, monitoring of cardiac and metabolic markers, and drug screening.

As healthcare systems evolve and consumers become more proactive about their health, there is a growing emphasis on the need for testing solutions that are not only user-friendly but also cost-effective and reliable. This trend is reinforced by the ongoing desire for swift diagnostic capabilities, which enhance timely decision-making in clinical settings. Consequently, the kits and reagents segment is projected to sustain its stronghold in the market, fueling continuous innovation and growth within the lateral flow assay industry in the years to come.

By end user, hospitals & clinics is estimated to be the largest segment through the study period.

The lateral flow assay (LFA) market is prominently segmented based on end users, with hospitals and clinics accounting for the largest share in 2024 and through the projection period. LFAs play a critical role in providing rapid, point-of-care diagnostics for a wide range of applications, including infectious disease detection, monitoring cardiac markers, conducting pregnancy and fertility tests, and facilitating drug screening. The immediacy of results enables healthcare professionals to make prompt clinical decisions, enhancing patient throughput and outcomes, particularly in urgent care settings where timely intervention is crucial.

The ongoing advancements in assay performance are further driving the adoption of LFAs within hospitals and clinics, as these improvements enhance sensitivity, specificity, and reliability. Additionally, the global shift toward quick and efficient diagnostic solutions, fueled by the recent emphasis on decentralized healthcare, supports the increasing integration of LFAs into clinical workflows. The future of LFAs in hospitals and clinics is set for substantial growth, fueled by technological advancements and increased demand for rapid diagnostics. These innovative tests promise faster and more accurate results, enhancing patient care and improving health outcomes. LFAs are poised to become essential tools in transforming the healthcare landscape.

 

North America is projected to lead the market among regions.

North America leads the global lateral flow assays market due to its advanced healthcare infrastructure, high healthcare spending, and strong presence of key medical device manufacturers. The rising geriatric population, increasing incidence of chronic diseases and infectious diseases, STIs, and quick adoption of new and innovative products are responsible for North America’s dominance in the lateral flow assays market.

The LFA market in the US is expected to offer lucrative growth opportunities due to the presence of several large hospitals and health systems, changing regulations, and the rising geriatric population in the country. As the demand for advanced healthcare solutions increases, the LFA sector is likely to see innovations in technology and patient care. Moreover, the trend toward value-based care is driving healthcare providers to seek efficient and effective LFA solutions. Most global players are also based in the US, which serves as a hub for research and development, helping to foster a competitive landscape that encourages new entrants and continuous improvement. With increasing investments in healthcare infrastructure and technology, the US is positioned to lead the way in shaping the future of the LFA market.

Robust investment in R&D, favorable reimbursement policies, and an established medical device ecosystem position North America as the dominant region in the lateral flow assays market, with continued growth anticipated.

Lateral Flow Assays Market
HOSPITALS & CLINICS LARGEST MARKET SHARE IN NORTH AMERICA IN 2024
US: FASTEST-GROWING COUNTRY MARKET

Recent Developments of Lateral Flow Assays Market

  • In July 2022, MedLab (2022), Abbott highlighted a suite of new immunochromatographic rapid tests, LFA-based for HCV antibody, H.?pylori antibody, and hepatitis B surface antigen, with high sensitivity, finger-stick formats
  • In May 2022, bioMerieux SA (France) acquired Specific Diagnostics Ltd. (US). The acquisition will help the company to develop a rapid antimicrobial susceptibility test (AST) system.

Key Market Players

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Product, Application, Technique, Sample Type, and End User
Geographies covered North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries

Frequently Asked Questions (FAQ)

Which are the top industry players in the lateral flow assays market?

The key players in this market are Abbott Laboratories (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), and QuidelOrtho Corporation (US).

What are some of the major drivers for this market?

The lateral flow assays market is driven by the persistent rise in infectious diseases worldwide, which demands fast, accessible diagnostics—boosting adoption of LFAs in hospitals, clinics, homes, and remote settings.

Which products have been included in the global lateral flow assays market?

The product-based segments include lateral flow readers and kits & reagents. The kits & reagents segment dominated the market in 2024 due to high demand for rapid, point-of-care, and home diagnostics for infectious diseases, pregnancy, cardiac/metabolic markers, and drug screening.

Which end users have been included in the global lateral flow assays market?

The end-user segments are Hospitals & Clinics, Home Care Settings, Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies, and Other End Users.

Which region is lucrative for global lateral flow assays market?

The Asia Pacific region is expected to witness the highest CAGR during the forecast period, driven by an aging population and rising incidence of infectious and chronic diseases.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Lateral Flow Assays Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
35
RESEARCH METHODOLOGY
40
EXECUTIVE SUMMARY
53
PREMIUM INSIGHTS
57
MARKET OVERVIEW
60
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - High prevalence of infectious diseases
    - Rising geriatric population
    - Growing use of home-based lateral flow assay devices
    - Growing demand for POC testing
    RESTRAINTS
    - Inconsistent results of lateral flow assay tests
    OPPORTUNITIES
    - Evolving applications of lateral flow assays
    - Rising demand for lateral flow assays in food & beverage industry
    - Emergence of Omicron COVID variant
    CHALLENGES
    - Limited reimbursements for lateral flow assay products
    - Difficulties in procuring quality raw materials to develop tests
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND, BY APPLICATION
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5 ECOSYSTEM
  • 5.6 SUPPLY CHAIN ANALYSIS
    PROMINENT COMPANIES
    SMALL & MEDIUM-SIZED COMPANIES
    END USERS
  • 5.7 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS
    TOP APPLICANTS (COMPANIES) OF LATERAL FLOW ASSAY PATENTS
    JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN LATERAL FLOW ASSAYS MARKET
  • 5.8 VALUE CHAIN ANALYSIS
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGY: LATERAL FLOW ASSAYS
    ADJACENT TECHNOLOGY: ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAYS)
  • 5.10 CASE STUDY ANALYSIS
    CASE STUDY 1: QUIDEL LAUNCHES NEW TEST WITH BROADER DETECTION WINDOW
    CASE STUDY 2: ABINGTON OFFERS HIGH-SENSITIVITY TESTS FOR GREATER QUALITY
    CASE STUDY 3: SIEMENS OFFERS HIGH-SENSITIVITY TROPONIN I ASSAY TO RAPIDLY DETECT ACUTE MYOCARDIAL INFARCTION
  • 5.11 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Rest of the world
  • 5.12 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 ADJACENT MARKET ANALYSIS
  • 5.14 KEY CONFERENCES AND EVENTS, 2023–2024
  • 5.15 TRADE ANALYSIS
    IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS
    EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS
  • 5.16 INDUSTRY TRENDS
    DETECTION OF HIV WITH LATERAL FLOW ASSAYS
    INCREASING ADOPTION OF QUANTITATIVE LATERAL FLOW ASSAYS DUE TO AVAILABILITY OF LFA READERS
  • 5.17 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.18 LATERAL FLOW ASSAYS MARKET: IMPACT OF INFLATION AND RECESSION
  • 5.19 ARTIFICIAL INTELLIGENCE (AI) IN LATERAL FLOW ASSAY MARKET
  • 5.20 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.21 INVESTMENT/VENTURE CAPITAL
LATERAL FLOW ASSAYS MARKET, BY PRODUCT
87
  • 6.1 INTRODUCTION
  • 6.2 KITS & REAGENTS
    RISING DEMAND FOR POC TESTING TO DRIVE MARKET
  • 6.3 READERS
    DIGITAL/HANDHELD READERS
    - Technological evolutions and accuracy to drive adoption
    BENCHTOP READERS
    - Lower diagnosis cost per patient to drive adoption
    INSIGHTS ON DISPOSABLE AND REUSABLE LATERAL FLOW ASSAY READERS
    LATERAL FLOW READERS MARKET FOR CLINICAL DIAGNOSTICS, BY TYPE
LATERAL FLOW ASSAYS MARKET, BY APPLICATION
98
  • 7.1 INTRODUCTION
  • 7.2 CLINICAL TESTING
    INFECTIOUS DISEASE TESTING
    - Mosquito-borne diseases
    - COVID-19
    - Influenza
    - Sexually transmitted infections
    - Hepatitis
    - Tuberculosis
    - Other infectious diseases
    CARDIAC MARKER TESTING
    - Troponin I & T
    - CK-MB
    - BNP & NT-proBNP
    - Myoglobin
    - D-Dimer
    - Other cardiac marker tests
    PREGNANCY & FERTILITY TESTING
    - Pregnancy testing
    - Fertility testing
    CHOLESTEROL/LIPID TESTING
    - Lifestyle changes, rising obesity prevalence to drive market
    DRUGS-OF-ABUSE TESTING
    - Technological advancements and rising focus on workplace drug testing to drive market
    OTHER CLINICAL TESTS
  • 7.3 VETERINARY DIAGNOSTICS
    INFECTIOUS DISEASE OUTBREAKS TO DRIVE MARKET
  • 7.4 FOOD SAFETY & ENVIRONMENT TESTING
    HIGH SENSITIVITY AND EASE OF USE TO BOOST DEMAND FOR ASSAYS
  • 7.5 DRUG DEVELOPMENT & QUALITY TESTING
    INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO SUPPORT MARKET GROWTH
LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE
148
  • 8.1 INTRODUCTION
  • 8.2 SANDWICH ASSAYS
    WIDE APPLICATIONS IN CLINICAL TESTING TO SUPPORT MARKET GROWTH
  • 8.3 COMPETITIVE ASSAYS
    REDUCED SELECTIVITY AND SENSITIVITY COMPARED TO SANDWICH ASSAYS TO HAMPER GROWTH
  • 8.4 MULTIPLEX DETECTION ASSAYS
    INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET
LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE
155
  • 9.1 INTRODUCTION
  • 9.2 BLOOD SAMPLES
    INCREASING USE OF BLOOD SAMPLES FOR INFECTIOUS DISEASE TESTING TO DRIVE MARKET
  • 9.3 URINE SAMPLES
    GROWING USE OF URINE SAMPLES FOR PREGNANCY AND DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
  • 9.4 SALIVA SAMPLES
    EASY AND LOW-COST COLLECTION, TRANSPORT, AND ANALYSIS OF SALIVA SAMPLES TO SUPPORT ADOPTION
  • 9.5 OTHER SAMPLES
LATERAL FLOW ASSAYS MARKET, BY END USER
161
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & CLINICS
    INCREASING USE OF POC TESTS TO DRIVE MARKET
  • 10.3 HOME CARE SETTINGS
    GROWING ACCEPTANCE OF REMOTE MONITORING TO PROPEL MARKET
  • 10.4 DIAGNOSTIC LABORATORIES
    LABORATORY TESTING LARGELY PREFERRED OVER PROFESSIONAL SETTINGS FOR URINE AND BLOOD TESTING
  • 10.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    INCREASING FOCUS ON PRODUCT SAFETY TO DRIVE ADOPTION OF LATERAL FLOW ASSAYS
  • 10.6 OTHER END USERS
LATERAL FLOW ASSAYS MARKET, BY REGION
169
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - US to hold largest market share of global market, by country
    CANADA
    - Availability of research funding and implementation of favorable government initiatives to drive market
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Growing number of POC diagnostics centers to drive demand
    FRANCE
    - High prevalence of age-related chronic diseases and infectious diseases to drive market
    UK
    - Rising prevalence of obesity to propel market
    ITALY
    - Growing initiatives toward decentralization of medical services to support market growth
    SPAIN
    - Increasing focus of international organizations and domestic players on developing POC products to aid market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Growing adoption of lateral flow assays in veterinary diagnostics and drug development to drive market
    JAPAN
    - Increasing prevalence of age-related illnesses to drive market
    INDIA
    - Growing healthcare concerns and rising income levels to propel market growth
    AUSTRALIA
    - Increasing prevalence of infectious diseases, especially influenza, to drive market
    SOUTH KOREA
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - High private healthcare expenditure and rising geriatric population to drive market
    MEXICO
    - High prevalence of obesity and related chronic diseases to propel market
    ARGENTINA
    - Availability of health insurance to favor market growth
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TO DRIVE MARKET
    MIDDLE EAST & AFRICA: RECESSION IMPACT
    GCC COUNTRIES
    - GCC countries: Recession impact
COMPETITIVE LANDSCAPE
304
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    STARS
    PERVASIVE PLAYERS
    EMERGING LEADERS
    PARTICIPANTS
    COMPANY FOOTPRINT
  • 12.6 COMPANY EVALUATION MATRIX: SMES & STARTUPS
    PROGRESSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    RESPONSIVE COMPANIES
    COMPETITIVE BENCHMARKING
  • 12.7 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
  • 12.8 R&D ASSESSMENT OF KEY PLAYERS
  • 12.9 INVESTMENT LANDSCAPE
  • 12.10 VALUATION AND FINANCIAL MATRICES
COMPANY PROFILES
324
  • 13.1 KEY PLAYERS
    ABBOTT LABORATORIES
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    QUIDELORTHO CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX SA
    - Business overview
    - Products offered
    - Recent developments
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    PERKINELMER INC.
    - Business overview
    - Products offered
    - Recent developments
    QIAGEN N.V.
    - Business overview
    - Products offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    MERCK KGAA
    HOLOGIC, INC.
    ABCAM PLC
    SURMODICS INC.
    CHEMBIO DIAGNOSTICS, INC. (BIOSYNEX)
    ORASURE TECHNOLOGIES
    DCN DIAGNOSTICS
    POLYSCIENCES INC.
    ABINGDON HEALTH
    ORANOXIS INC.
    AESKU.GROUP GMBH
    BIO GROUP MEDICAL SYSTEM S.R.L
    PHARMACT GMBH
    DIESSE DIAGNOSTICA SENESE S.P.A.
    XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
APPENDIX
374
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 PREVALENCE OF HIV WORLDWIDE (2017 VS. 2021)
  • TABLE 3 LIST OF COMMERCIALLY AVAILABLE SALIVA LFA PRODUCTS
  • TABLE 4 EPIDEMIOLOGICAL UPDATE ON OMICRON VARIANT
  • TABLE 5 EXAMPLES OF LATERAL FLOW ASSAY KITS AVAILABLE TO DETECT OMICRON
  • TABLE 6 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAYS (KITS & REAGENTS), BY COMPANY AND APPLICATION, 2021–2023
  • TABLE 7 AVERAGE SELLING PRICE OF LATERAL FLOW ANALYZERS, BY REGION, 2020 VS. 2022
  • TABLE 8 LATERAL FLOW ASSAYS MARKET: ECOSYSTEM ANALYSIS (2022)
  • TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 LATERAL FLOW ASSAYS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 15 LATERAL FLOW ASSAYS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • TABLE 16 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 17 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2018–2022 (USD MILLION)
  • TABLE 18 US: HIV PREVALENCE RATE, 2016–2021
  • TABLE 19 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS
  • TABLE 20 POTENTIAL APPLICATIONS OF AI IN LATERAL FLOW ASSAYS
  • TABLE 21 LATERAL FLOW ASSAYS MARKET: UNMET NEEDS/END-USER EXPECTATIONS
  • TABLE 22 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 23 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 24 LATERAL FLOW READERS OFFERED, BY COMPANY
  • TABLE 25 INDICATIVE LIST OF LATERAL FLOW ASSAY KITS & REAGENTS: WITH AND WITHOUT ANALYZERS
  • TABLE 26 LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 27 LATERAL FLOW READERS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 28 DIGITAL/HANDHELD LATERAL FLOW READERS MARKET, BY COUNTRY, 2021–2029 (USD MILLION).
  • TABLE 29 BENCHTOP LATERAL FLOW READERS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 30 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW READERS FOR CLINICAL DIAGNOSTICS
  • TABLE 31 LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 32 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 33 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 34 LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 35 LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 36 MAJOR PRODUCTS: DENGUE TESTING
  • TABLE 37 LATERAL FLOW ASSAYS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 38 COVID-19 (ANTIGEN AND ANTIBODY) LATERAL FLOW ASSAY TESTS
  • TABLE 39 LATERAL FLOW ASSAYS MARKET FOR COVID-19, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 40 LATERAL FLOW ASSAYS MARKET FOR INFLUENZA, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 41 LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 42 LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 43 LATERAL FLOW ASSAYS MARKET FOR HIV, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 44 LATERAL FLOW ASSAYS MARKET FOR HPV, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 45 LATERAL FLOW ASSAYS MARKET FOR CHLAMYDIA, BY COUNTRY, 2021–2029
  • TABLE 46 LATERAL FLOW ASSAYS MARKET FOR GONORRHEA, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 47 LATERAL FLOW ASSAYS MARKET FOR SYPHILIS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 48 LATERAL FLOW ASSAYS MARKET FOR OTHER SEXUALLY TRANSMITTED INFECTIONS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 49 LATERAL FLOW ASSAYS MARKET FOR HEPATITIS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 50 LATERAL FLOW ASSAYS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 51 LATERAL FLOW ASSAYS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 52 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 53 LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 54 LATERAL FLOW ASSAYS MARKET FOR TROPONIN I & T TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 55 LATERAL FLOW ASSAYS MARKET FOR CK-MB TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 56 LATERAL FLOW ASSAYS MARKET FOR BNP & NT-PROBNP TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 57 LATERAL FLOW ASSAYS MARKET FOR MYOGLOBIN TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 58 LATERAL FLOW ASSAYS MARKET FOR D-DIMER TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 59 LATERAL FLOW ASSAYS MARKET FOR OTHER CARDIAC MARKER TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 60 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 61 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 62 LATERAL FLOW ASSAYS MARKET FOR PREGNANCY TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 63 LATERAL FLOW ASSAYS MARKET FOR FERTILITY TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 64 LATERAL FLOW ASSAYS MARKET FOR CHOLESTEROL/LIPID TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 65 LATERAL FLOW ASSAYS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 66 LATERAL FLOW ASSAYS MARKET FOR OTHER CLINICAL TESTS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 67 LATERAL FLOW ASSAYS MARKET FOR VETERINARY DIAGNOSTICS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 68 LATERAL FLOW ASSAYS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 69 LATERAL FLOW ASSAYS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 70 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 71 LATERAL FLOW SANDWICH ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 72 LATERAL FLOW COMPETITIVE ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 73 LATERAL FLOW MULTIPLEX DETECTION ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 74 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 75 LATERAL FLOW ASSAYS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 76 LATERAL FLOW ASSAYS MARKET FOR URINE SAMPLES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 77 LATERAL FLOW ASSAYS MARKET FOR SALIVA SAMPLES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 78 LATERAL FLOW ASSAYS MARKET FOR OTHER SAMPLES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 79 LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 80 LATERAL FLOW ASSAYS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 81 LATERAL FLOW ASSAYS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 82 LATERAL FLOW ASSAYS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 83 LATERAL FLOW ASSAYS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 84 LATERAL FLOW ASSAYS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 85 LATERAL FLOW ASSAYS MARKET, BY REGION, 2021–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 87 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 99 US: MACROECONOMIC INDICATORS
  • TABLE 100 US: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 101 US: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 102 US: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 103 US: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 104 US: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 105 US: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 106 US: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 107 US: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 108 US: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 109 US: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 110 US: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029USD MILLION)
  • TABLE 111 CANADA: MACROECONOMIC INDICATORS
  • TABLE 112 CANADA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 113 CANADA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 114 CANADA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 115 CANADA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 116 CANADA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 117 CANADA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 118 CANADA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 119 CANADA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 120 CANADA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 121 CANADA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 122 CANADA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029USD MILLION)
  • TABLE 123 EUROPE: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 124 EUROPE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 125 EUROPE: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 126 EUROPE: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 127 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 128 EUROPE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 129 EUROPE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 130 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 131 EUROPE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 132 EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 133 EUROPE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 134 EUROPE: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 135 GERMANY: MACROECONOMIC INDICATORS
  • TABLE 136 GERMANY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 137 GERMANY: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 138 GERMANY: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 139 GERMANY: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 140 GERMANY: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 141 GERMANY: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 142 GERMANY: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 143 GERMANY: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 144 GERMANY: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 145 GERMANY: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 146 GERMANY: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 147 FRANCE: MACROECONOMIC INDICATORS
  • TABLE 148 FRANCE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 149 FRANCE: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 150 FRANCE: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 151 FRANCE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 152 FRANCE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 153 FRANCE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 154 FRANCE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 155 FRANCE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 156 FRANCE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 157 FRANCE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 158 FRANCE: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 159 UK: MACROECONOMIC INDICATORS
  • TABLE 160 UK: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 161 UK: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 162 UK: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 163 UK: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 164 UK: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 165 UK: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 166 UK: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 167 UK: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 168 UK: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 169 UK: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 170 UK: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 171 ITALY: MACROECONOMIC INDICATORS
  • TABLE 172 ITALY: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 173 ITALY: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 174 ITALY: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 175 ITALY: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 176 ITALY: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 177 ITALY: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 178 ITALY: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 179 ITALY: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 180 ITALY: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 181 ITALY: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 182 ITALY: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 183 SPAIN: MACROECONOMIC INDICATORS
  • TABLE 184 SPAIN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 185 SPAIN: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 186 SPAIN: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 187 SPAIN: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 188 SPAIN: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 189 SPAIN: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 190 SPAIN: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 191 SPAIN: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 192 SPAIN: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 193 SPAIN: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 194 SPAIN: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 195 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 196 REST OF EUROPE: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 197 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 198 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 199 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 200 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 201 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 202 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 203 REST OF EUROPE: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 204 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 205 REST OF EUROPE: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 206 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 218 CHINA: MACROECONOMIC INDICATORS
  • TABLE 219 CHINA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 220 CHINA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 221 CHINA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 222 CHINA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 223 CHINA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 224 CHINA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 225 CHINA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 226 CHINA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 227 CHINA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 228 CHINA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 229 CHINA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 230 JAPAN: MACROECONOMIC INDICATORS
  • TABLE 231 JAPAN: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 232 JAPAN: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 233 JAPAN: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 234 JAPAN: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 235 JAPAN: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 236 JAPAN: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 237 JAPAN: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 238 JAPAN: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 239 JAPAN: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 240 JAPAN: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 241 JAPAN: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 242 INDIA: MACROECONOMIC INDICATORS
  • TABLE 243 INDIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 244 INDIA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 245 INDIA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 246 INDIA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 247 INDIA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 248 INDIA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 249 INDIA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 250 INDIA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 251 INDIA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 252 INDIA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 253 INDIA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 254 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 255 AUSTRALIA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 256 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 257 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 258 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 259 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 260 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 261 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 262 AUSTRALIA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 263 AUSTRALIA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 264 AUSTRALIA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 265 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 266 SOUTH KOREA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 267 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 268 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 269 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 270 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 271 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 272 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 273 SOUTH KOREA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 274 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 275 SOUTH KOREA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 287 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY COUNTRY, 2021–2029 (USD MILLION)
  • TABLE 288 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 289 LATIN AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 290 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 291 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 292 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 293 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 294 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 295 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 296 LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 299 BRAZIL: MACROECONOMIC INDICATORS
  • TABLE 300 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 301 BRAZIL: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 302 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 303 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 304 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 305 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 306 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 307 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 308 BRAZIL: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 309 BRAZIL: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 310 BRAZIL: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 311 MEXICO: MACROECONOMIC INDICATORS
  • TABLE 312 MEXICO: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 313 MEXICO: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 314 MEXICO: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 315 MEXICO: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 316 MEXICO: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 317 MEXICO: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 318 MEXICO: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 319 MEXICO: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 320 MEXICO: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 321 MEXICO: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 322 MEXICO: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 323 ARGENTINA: MACROECONOMIC INDICATORS
  • TABLE 324 ARGENTINA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 325 ARGENTINA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 326 ARGENTINA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 327 ARGENTINA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 328 ARGENTINA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 329 ARGENTINA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 330 ARGENTINA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 331 ARGENTINA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 332 ARGENTINA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 333 ARGENTINA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 334 ARGENTINA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 336 REST OF LATIN AMERICA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 337 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 338 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 339 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 340 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 341 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 342 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 343 REST OF LATIN AMERICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 344 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 345 REST OF LATIN AMERICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 346 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 347 MIDDLE EAST & AFRICA: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 348 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 349 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 357 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2021–2029 (USD MILLION)
  • TABLE 358 GCC COUNTRIES: LATERAL FLOW READERS MARKET, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 359 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2021–2029 (USD MILLION)
  • TABLE 360 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 361 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET FOR INFECTIOUS DISEASE TESTING, BY DISEASE TYPE, 2021–2029 (USD MILLION)
  • TABLE 362 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET FOR SEXUALLY TRANSMITTED INFECTIONS, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 363 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET FOR CARDIAC MARKER TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET FOR PREGNANCY & FERTILITY TESTING, BY TYPE, 2021–2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2021–2029 (USD MILLION)
  • TABLE 366 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2021–2029 (USD MILLION)
  • TABLE 367 GCC COUNTRIES: LATERAL FLOW ASSAYS MARKET, BY END USER, 2021–2029 (USD MILLION)
  • TABLE 368 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN LATERAL FLOW ASSAYS MARKET
  • TABLE 369 LATERAL FLOW ASSAYS MARKET: DEGREE OF COMPETITION
  • TABLE 370 PRODUCT FOOTPRINT (25 COMPANIES)
  • TABLE 371 TECHNIQUE FOOTPRINT (25 COMPANIES)
  • TABLE 372 APPLICATION FOOTPRINT (25 COMPANIES)
  • TABLE 373 SAMPLE TYPE FOOTPRINT (25 COMPANIES)
  • TABLE 374 END-USER FOOTPRINT (25 COMPANIES)
  • TABLE 375 REGIONAL FOOTPRINT (25 COMPANIES)
  • TABLE 376 LATERAL FLOW ASSAY MARKET: DETAILED LIST OF KEY STARTUP/SMES
  • TABLE 377 LATERAL FLOW ASSAY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUP/SMES
  • TABLE 378 LATERAL FLOW ASSAYS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2020–DECEMBER 2023
  • TABLE 379 LATERAL FLOW ASSAYS MARKET: DEALS, JANUARY 2020–DECEMBER 2023
  • TABLE 380 LATERAL FLOW ASSAYS MARKET: EXPANSIONS (JANUARY 2020–DECEMBER 2023)
  • TABLE 381 LATERAL FLOW ASSAYS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–DECEMBER 2023
  • TABLE 382 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 383 ABBOTT LABORATORIES: PRODUCTS OFFERED
  • TABLE 384 ABBOTT LABORATORIES: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 385 ABBOTT LABORATORIES: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 386 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 387 F. HOFFMAN-LA ROCHE: PRODUCTS OFFERED
  • TABLE 388 F. HOFFMAN-LA ROCHE: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 389 F. HOFFMAN-LA ROCHE: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 390 F. HOFFMAN-LA ROCHE: EXPANSIONS (JANUARY 2020–DECEMBER 2023)
  • TABLE 391 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 392 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 393 QUIDELORTHO CORPORATION: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 394 QUIDELORTHO CORPORATION: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 395 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 396 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 397 DANAHER CORPORATION: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 398 SIEMENS AG: COMPANY OVERVIEW
  • TABLE 399 SIEMENS AG: PRODUCTS OFFERED
  • TABLE 400 SIEMENS AG: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 401 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 402 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 403 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 404 BECTON, DICKINSON AND COMPANY: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 405 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS (JANUARY 2020–DECEMBER 2023)
  • TABLE 406 BIOMÉRIEUX SA: COMPANY OVERVIEW
  • TABLE 407 BIOMÉRIEUX SA: PRODUCTS OFFERED
  • TABLE 408 BIOMÉRIEUX SA: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 409 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 410 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 411 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 412 THERMO FISHER SCIENTIFIC INC.: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 413 PERKINELMER INC.: COMPANY OVERVIEW
  • TABLE 414 PERKINELMER INC.: PRODUCTS OFFERED
  • TABLE 415 PERKINELMER INC.: PRODUCT LAUNCHES (JANUARY 2020–DECEMBER 2023)
  • TABLE 416 PERKINELMER INC.: DEALS (JANUARY 2020–DECEMBER 2023)
  • TABLE 417 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 418 QIAGEN N.V.: PRODUCTS OFFERED
  • TABLE 419 QIAGEN N.V.: DEALS (JANUARY 2020–DECEMBER 2023)
LIST OF FIGURES
 
  • FIGURE 1 LATERAL FLOW ASSAYS MARKET SEGMENTATION
  • FIGURE 2 REGIONAL SCOPE
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
  • FIGURE 6 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2022)
  • FIGURE 7 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAYS MARKET (2022)
  • FIGURE 8 APPROACH 3: DEMAND-SIDE APPROACH, BASED ON MALARIA LATERAL FLOW TESTING MARKET SIZE (2022)
  • FIGURE 9 APPROACH 4: TOP-DOWN APPROACH
  • FIGURE 10 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2029): IMPACT ON MARKET GROWTH AND CAGR
  • FIGURE 11 CAGR PROJECTIONS
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
  • FIGURE 13 LATERAL FLOW ASSAYS MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION)
  • FIGURE 14 LATERAL FLOW ASSAY KITS & REAGENTS MARKET, BY TECHNIQUE, 2023 VS. 2029 (USD MILLION)
  • FIGURE 15 LATERAL FLOW ASSAYS MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION)
  • FIGURE 16 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING, BY SAMPLE TYPE, 2023 VS. 2029 (USD MILLION)
  • FIGURE 17 LATERAL FLOW ASSAYS MARKET, BY END USER, 2023 VS. 2029 (USD MILLION)
  • FIGURE 18 LATERAL FLOW ASSAYS MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 19 HIGH PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD
  • FIGURE 21 CLINICAL TESTING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
  • FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD
  • FIGURE 23 EMERGING ECONOMIES TO OFFER HIGH GROWTH OPPORTUNITIES IN FORECAST PERIOD
  • FIGURE 24 LATERAL FLOW ASSAYS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 GERIATRIC POPULATION, BY REGION, 2020 VS. 2050 (MILLION)
  • FIGURE 26 GERIATRIC POPULATION, BY REGION, 2022 VS. 2030 VS. 2050 (% OF TOTAL POPULATION)
  • FIGURE 27 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN LATERAL FLOW ASSAYS MARKET, 2013–2023
  • FIGURE 29 TOP COMPANIES THAT APPLIED FOR LATERAL FLOW ASSAY PATENTS, 2016–2022
  • FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAY PATENTS, 2016–2022
  • FIGURE 31 LATERAL FLOW ASSAYS MARKET: VALUE CHAIN ANALYSIS (2022)
  • FIGURE 32 LATERAL FLOW ASSAYS: OVERVIEW OF ADJACENT MARKETS
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS
  • FIGURE 34 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
  • FIGURE 35 LATERAL FLOW ASSAYS MARKET: INVESTMENT/VENTURE CAPITAL SCENARIO, 2018–2022
  • FIGURE 36 PRODUCT PORTFOLIO ANALYSIS OF LATERAL FLOW READERS FOR CLINICAL DIAGNOSTICS (2022)
  • FIGURE 37 NORTH MARKET SIZING FOR COVID-19: SCENARIO-BASED FORECASTING
  • FIGURE 38 CHINA TO WITNESS HIGHEST GROWTH IN FORECAST PERIOD
  • FIGURE 39 NORTH AMERICA: LATERAL FLOW ASSAYS MARKET SNAPSHOT
  • FIGURE 40 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET SNAPSHOT
  • FIGURE 41 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN PAST FIVE YEARS
  • FIGURE 42 LATERAL FLOW ASSAYS MARKET SHARE ANALYSIS, BY KEY PLAYER (2022)
  • FIGURE 43 LATERAL FLOW ASSAYS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2022
  • FIGURE 44 COMPANY FOOTPRINT (25 COMPANIES)
  • FIGURE 45 LATERAL FLOW ASSAYS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2022
  • FIGURE 46 R&D EXPENDITURE: MAJOR PLAYERS IN LATERAL FLOW ASSAYS MARKET, 2021 VS. 2022
  • FIGURE 47 LATERAL FLOW ASSAY MARKET FUNDING SOARED IN 2022
  • FIGURE 48 MOST VALUED LATERAL FLOW ASSAY FIRMS IN 2022 (USD BILLION)
  • FIGURE 49 LATERAL FLOW ASSAYS MARKET: VALUATION AND FINANCIAL MATRICES
  • FIGURE 50 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
  • FIGURE 51 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
  • FIGURE 52 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 53 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 54 SIEMENS AG: COMPANY SNAPSHOT (2022)
  • FIGURE 55 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
  • FIGURE 56 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2022)
  • FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 58 PERKINELMER INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 59 QIAGEN N.V.: COMPANY SNAPSHOT (2022)

The study involved major activities in estimating the current market size for the global lateral flow assays market.

Exhaustive secondary research was done to collect information on the lateral flow assays industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the lateral flow assays market.

The four steps involved in estimating the market size are:

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases, white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as US Food and Drug Administration, World Health Organization (WHO), Centers for Disease Control and Prevention, International Organization for Standardization (ISO), Agency for Healthcare Research and Quality, were referred to identify and collect information for the global lateral flow assays market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends, to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the lateral flow assays market. The primary sources from the demand side include hospitals, clinics, diagnostic laboratories, pharmaceutical and biotechnology companies. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.

The following is a breakdown of the primary respondents:

Lateral Flow Assays Market

Note 1: Other designations include sales managers, marketing managers, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For the global market value, annual revenues were calculated based on the revenue mapping of major product manufacturers and OEMs active in the global lateral flow assays market. All the major service providers were identified at the global and/or country/regional level. Revenue mapping for the respective business segments/sub-segments was done for the major players. The global lateral flow assays market was split into various segments and sub-segments based on:

  • List of major players operating in the market at the regional and/or country level
  • Product mapping of lateral flow assay providers at the regional and/or country level
  • Mapping of annual revenue generated by listed major players from lateral flow assays (or the nearest reported business unit/product category)
  • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
  • Summation of the market value of all segments/subsegments to arrive at the global lateral flow assays market

The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

The research methodology used to estimate the market size includes the following:

Lateral Flow Assays Market

Data Triangulation

After arriving at the overall market size by applying the process mentioned above, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Lateral flow assays, or lateral flow immunochromatographic assays, are simple-to-use diagnostic devices to confirm the presence or absence of a target analyte, such as pathogens or biomarkers in humans or animals, or contaminants in water supplies, without requiring specialized equipment.

Stakeholders

  • Lateral flow assay product manufacturers
  • Lateral flow assay vendors and distributors
  • Hospitals
  • Clinical and diagnostic laboratories
  • Pharmaceutical and biotechnological companies
  • Venture capitalists and investors

Report Objectives

  • To define, describe, analyze, and forecast the lateral flow assays (LFA) market by product, application, technique, sample type, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall lateral flow assays market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries.
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
  • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

 

Previous Versions of this Report

Lateral Flow Assays Market by Product (Kits, Readers), Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environmental Testing), Technique (Sandwich, Multiplex Detection Assay), End User (Hospitals, Home care) & Region - Global Forecast to 2029

Report Code MD 4158
Published in Feb, 2024, By MarketsandMarkets™

Lateral Flow Assays Market by Product (Kits, Readers), Application (Clinical Testing, Veterinary Diagnostics, Food Safety & Environmental Testing), Technique (Sandwich, Multiplex Detection Assay), End User (Hospitals, Home care) - Global Forecast to 2027

Report Code MD 4158
Published in Feb, 2023, By MarketsandMarkets™

Lateral Flow Assays Market by Application (Clinical Testing (Pregnancy, Infectious Diseases (Mosquito, Influenza, STI, Hepatitis, TB) Cardiac Marker Lipid Test) Veterinary, Food Safety) Product (Readers, Kits) Technique, End User - Global Forecast to 2026

Report Code MD 4158
Published in Dec, 2021, By MarketsandMarkets™

Lateral Flow Assays Market by Application (Clinical Testing (Pregnancy, Infectious Diseases (Mosquito, Influenza, STI, Hepatitis, TB) Cardiac Marker Lipid Test) Veterinary, Food Safety), Product, Technique, End User - Global Forecast to 2025

Report Code MD 4158
Published in Nov, 2020, By MarketsandMarkets™

Lateral Flow Assay Market by Application (Clinical Testing (Pregnancy, Infectious Disease (Mosquito , Influenza, STI, Hepatitis, TB), Cardiac Marker, Lipid Test) Veterinary, Food Safety) Product (Reader, Kits) Technique, End User - Global Forecast to 2023

Report Code MD 4158
Published in Nov, 2018, By MarketsandMarkets™

Lateral Flow Assay Market by Product (Reader, Kit), Application (Clinical (Pregnancy, Infectious Disease, Lipid, Cardiac Marker), Veterinary, Drug Development, Food Safety), Technique (Competitive, Multiplex, Sandwich), End User - Global Forecast to 2022

Report Code MD 4158
Published in Aug, 2017, By MarketsandMarkets™

Lateral Flow Assay Market by Product (Reader, Kits) Application (Clinical Testing (Pregnancy, Infectious Disease, Cholestrol, Cardiac Marker), Veterinary, Drug Development) Technique (Sandwich, Competitive, Multiplex) End User - Global Forecast to 2020

Report Code MD 4158
Published in Mar, 2016, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Lateral Flow Assays Market

User

Nov, 2019

this is good.

Max

Oct, 2022

Which factors plays the vital role the global growth of Lateral Flow Assays Market?.

User

Jun, 2018

this is good.

DMCA.com Protection Status